Two Sigma Advisers LP Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Two Sigma Advisers LP grew its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 1.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,349,211 shares of the company's stock after purchasing an additional 16,800 shares during the period. Two Sigma Advisers LP owned approximately 0.85% of Ionis Pharmaceuticals worth $47,168,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Xponance Inc. raised its stake in shares of Ionis Pharmaceuticals by 1.7% during the fourth quarter. Xponance Inc. now owns 19,339 shares of the company's stock valued at $676,000 after purchasing an additional 318 shares during the period. Amalgamated Bank increased its stake in shares of Ionis Pharmaceuticals by 3.4% in the fourth quarter. Amalgamated Bank now owns 10,292 shares of the company's stock worth $360,000 after buying an additional 335 shares during the last quarter. Vontobel Holding Ltd. increased its stake in shares of Ionis Pharmaceuticals by 6.6% in the fourth quarter. Vontobel Holding Ltd. now owns 5,865 shares of the company's stock worth $205,000 after buying an additional 363 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Ionis Pharmaceuticals by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company's stock worth $763,000 after buying an additional 373 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its stake in shares of Ionis Pharmaceuticals by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 68,803 shares of the company's stock worth $2,405,000 after buying an additional 440 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company's stock.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Patrick R. O'neil sold 1,207 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the completion of the sale, the executive vice president now directly owns 56,245 shares of the company's stock, valued at approximately $1,819,525.75. This represents a 2.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael R. Hayden purchased 15,000 shares of the business's stock in a transaction on Thursday, May 1st. The stock was acquired at an average cost of $31.86 per share, with a total value of $477,900.00. Following the completion of the acquisition, the director now directly owns 50,219 shares in the company, valued at $1,599,977.34. The trade was a 42.59% increase in their position. The disclosure for this purchase can be found here. Insiders sold 2,027 shares of company stock worth $62,863 in the last 90 days. Corporate insiders own 2.60% of the company's stock.

Ionis Pharmaceuticals Stock Up 1.4%

Ionis Pharmaceuticals stock opened at $34.03 on Tuesday. The company has a 50-day simple moving average of $30.57 and a 200-day simple moving average of $33.14. The firm has a market capitalization of $5.42 billion, a P/E ratio of -11.19 and a beta of 0.15. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals, Inc. has a one year low of $23.95 and a one year high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.14. The business had revenue of $132.00 million during the quarter, compared to analyst estimates of $144.31 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The company's quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.98) earnings per share. As a group, equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on IONS shares. Royal Bank of Canada restated an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, February 20th. Redburn Atlantic started coverage on shares of Ionis Pharmaceuticals in a research note on Monday, March 31st. They issued a "neutral" rating and a $39.00 price target for the company. StockNews.com upgraded shares of Ionis Pharmaceuticals to a "sell" rating in a research note on Tuesday, March 18th. Guggenheim lowered their target price on shares of Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Citigroup lowered their target price on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $56.67.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.